Corient Private Wealth
RCUS icon

Corient Private Wealth’s Arcus Biosciences RCUS Stock Holding History

Corient Private Wealth’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$521K Sell
24,143
-20,989
-47% -$453K ﹤0.01% 2006
2025
Q4 		$1.08M Buy
45,132
+22,958
+104% +$468K ﹤0.01% 1844
2025
Q3 		$302K Buy
22,174
+107
+0.5% +$1.11K ﹤0.01% 2109
2025
Q2 		$180K Buy
+22,067
New +$188K ﹤0.01% 2259

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Corient Private Wealth's RCUS Position: Q1 2026 in Review

Corient Private Wealth reduced its Arcus Biosciences (RCUS) stake by 47% in Q1 2026, selling an estimated $453K and leaving 24,143 shares worth $521K. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

Corient Private Wealth first reported a position in RCUS in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.08M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Corient Private Wealth held 24,143 shares of Arcus Biosciences worth $521K as of Q1 2026.
  • Corient Private Wealth sold 20,989 Arcus Biosciences shares in Q1 2026, an estimated $453K.
  • Arcus Biosciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2006 holding.
  • Corient Private Wealth first reported a position in Arcus Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Corient Private Wealth's Arcus Biosciences position peaked at $1.08M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.